Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gaviscon raft formation gamma scintigraphy study in healthy volunteers
2011-002341-35Phase 2Completed
- Sponsor
- Reckitt
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of magnesium trisilicate and Gaviscon in gastroesophageal reflux disease (GERD) (4 arms), sponsored by Reckitt. Primary endpoint: Distribution of investigational medicinal product in the stomach at 5 minutes post dose. Started Jun 2011; status: completed.
02
Drugs
magnesium trisilicateGaviscon
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2011-002341-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002341-35.